206 related articles for article (PubMed ID: 18706932)
1. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.
Van Laethem K; Schrooten Y; Covens K; Dekeersmaeker N; De Munter P; Van Wijngaerden E; Van Ranst M; Vandamme AM
J Virol Methods; 2008 Nov; 153(2):176-81. PubMed ID: 18706932
[TBL] [Abstract][Full Text] [Related]
2. An HIV-1 integrase genotype assay for the detection of drug resistance mutations.
Hearps AC; Greengrass V; Hoy J; Crowe SM
Sex Health; 2009 Dec; 6(4):305-9. PubMed ID: 19917199
[TBL] [Abstract][Full Text] [Related]
3. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes.
Van Laethem K; Schrooten Y; Dedecker S; Van Heeswijck L; Deforche K; Van Wijngaerden E; Van Ranst M; Vandamme AM
J Virol Methods; 2006 Mar; 132(1-2):181-6. PubMed ID: 16271771
[TBL] [Abstract][Full Text] [Related]
4. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
5. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
[TBL] [Abstract][Full Text] [Related]
6. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene.
Van Laethem K; Schrooten Y; Lemey P; Van Wijngaerden E; De Wit S; Van Ranst M; Vandamme AM
J Virol Methods; 2005 Jan; 123(1):25-34. PubMed ID: 15582695
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes.
Snoeck J; Riva C; Steegen K; Schrooten Y; Maes B; Vergne L; Van Laethem K; Peeters M; Vandamme AM
J Virol Methods; 2005 Sep; 128(1-2):47-53. PubMed ID: 15871907
[TBL] [Abstract][Full Text] [Related]
8. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
[TBL] [Abstract][Full Text] [Related]
10. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
11. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
12. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
13. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
14. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
15. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
Wallis CL; Viana RV; Saravanan S; Silva de Jesus C; Zeh C; Halvas EK; Mellors JW
J Virol Methods; 2017 Mar; 241():41-45. PubMed ID: 27993614
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
[TBL] [Abstract][Full Text] [Related]
18. Performance comparison of an in-house integrase genotyping assay versus the ViroSeq™ Integra48, and study of HIV-1 integrase polymorphisms in Hong Kong.
To SW; Chen JH; Wong KH; Chan KC; Ng HM; Wu H; Lam JT; Yam WC
J Clin Virol; 2013 Sep; 58(1):299-302. PubMed ID: 23886504
[TBL] [Abstract][Full Text] [Related]
19. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.
Chen JH; Wong KH; Chan K; Lam HY; Lee SS; Li P; Lee MP; Tsang DN; Zheng BJ; Yuen KY; Yam WC
J Clin Virol; 2007 Jun; 39(2):125-31. PubMed ID: 17449318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]